Skip to content

News

What an f2 of 50 says about two dissolution profiles

  • News
  • 1 min read

After a site change, the first comparison of the old tablets with the new ones often comes down to one number, f2.

f2 is the similarity factor for two dissolution profiles. It averages the squared difference between the curves at each time point and puts it on a scale where 100 means identical. A difference of 10% at every point gives 49.9, which is where the limit of 50 comes from.

FDA's 1997 guidance on dissolution testing of immediate-release solid oral dosage forms treats f2 values of 50 to 100 as showing that two curves are equivalent. The EMA bioequivalence guideline says an f2 between 50 and 100 suggests that the two profiles are similar.

The FDA text attaches conditions to the number: 12 units of each product, the same time points under exactly the same conditions, and only one measurement after 85% dissolution of both products.

A caution for the receiving site: an f2 of 52 passes with the curves about 9% apart on average, and that gap usually has a cause on the shop floor, such as granulation end point, press speed or coating.

Assay, impurities, uniformity and stability carry the rest of the comparison.

Topics

Related

More on this subject

Where the 30-day deviation deadline comes from

The 2013 text of EU GMP Chapter 1 and 21 CFR 211.192 speak of recording and investigating deviations, and neither gives a number of days. The 30-day limit is the site's own, and inspectors hold a site to its procedure. The alternative is also a site rule: a limit per risk class, with extensions only on a written reason and an interim risk assessment.

InsightRead

10–15 Pa for FDA, 10 Pa for Annex 1: one cascade

FDA's 2004 aseptic guidance asks for at least 10–15 Pa between rooms of different classification; Annex 1 gives at least 10 Pa as guidance. Setting each cascade step at 15 Pa meets both. Holding it is harder: seals wear and filters load, so trend the differentials instead of waiting for alarms.

InsightRead